Abstract 225P
Background
Prostate cancer ranges from indolent to aggressive, with 10–20% of patients developing metastases. Immune cell interactions in the tumor microenvironment facilitate growth. This study aimed to characterize circulating immune cells in patients with oligometastatic (OMPC) and plurimetastatic prostate cancer (PMPC).
Methods
This retrospective cohort study included individuals with metastatic prostate cancer (mPC). Patients were classified into two groups: OMPC (five or fewer lesions in bone and/or lymph nodes via CT or bone scans), and PMPC, those not meeting OMPC criteria. Demographic data and immune cell subsets were collected at admission. After blood collection, peripheral blood mononuclear cells were isolated, and flow cytometry assessed various immune populations (γδ T cells, αβ T cells, Tregs, memory T cells, effector T cells, NK cells, NKT cells, B cells, myeloid cells, and monocytes) and cytokines (TNF-α, IFN-γ, IL-17). The Mann–Whitney U test was used for comparisons, with p ≤ 0.05 considered significant.
Results
43 patients were identified, with a median age of 64 years (50-80). 17 patients (39.5%) had OMPC and 26 (60.5%) had PMPC. 16 patients (37.2%) presented with de novo mPC. Bone was the most common metastatic site in both groups. Most patients (67.4%, n=29) received hormone therapy (HT) as first-line treatment , while 9 patients (20.9%) received chemotherapy plus HT. An increase in γδ2+ T cells (p=0.048) was noted in the OMPC group. There was a trend toward increased levels of γδ2+ expressing IFN-γ (p=0.066) in PMPC patients.
Conclusions
A significant increase in γδ2+ T cells was observed in OMPC. These cells are critical for immune modulation. Elevated levels in OMPC subgroup may indicate an active immune response, potentially providing a protective effect against tumor progression in this subgroup. Conversely, PMPC patients showed a trend toward increased IFN-γ expression in γδ2+ T cells (p=0.066). While these cells can produce IFN-γ, those in OMPC may be less activated, limiting their effectiveness and suggesting an immune escape mechanism. This study has limitations; results are exploratory and require confirmation in a larger cohort. We plan to validate the differences in γδ2+ T cells and IFN-γ expression in an independent group.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
145P - Penpulimab-based combination neoadjuvant/adjuvant therapy for patients with resectable locally advanced non-small cell lung cancer: An update of the phase II, prospective study (ALTER-L043)
Presenter: Changli Wang
Session: Poster Display session
Resources:
Abstract
146P - Neoadjuvant adebrelimab combined with chemotherapy for adenocarcinoma of esophagogastric junction: A single-arm, single-center, phase II clinical trial
Presenter: Jinqiang Liu
Session: Poster Display session
147P - Serplulimab combined with chemotherapy in the neoadjuvant treatment of resectable oesophageal squamous cell carcinoma: A single-arm phase II trial
Presenter: Zixiang Wu
Session: Poster Display session
148P - Neoadjuvant camrelizumab plus metronomic chemotherapy in patients with advanced esophageal squamous cell carcinomas: A randomized phase II trial
Presenter: JIE LIU
Session: Poster Display session
149P - Toripalimab and chemotherapy as first line combination in advanced thymic carcinoma: A prospective, single-arm, phase II trial
Presenter: Kai Zhu
Session: Poster Display session
150P - Interim results of the multicenter phase II study on induction pembrolizumab plus chemotherapy followed by radiotherapy in locally advanced head and neck cancer
Presenter: Tatiana Antonova
Session: Poster Display session
151P - Anti-tumor T cell response and immunoselection under combined GARP:TGF-?1/PD-1 blockade
Presenter: Grégoire de Streel
Session: Poster Display session
152P - TACTI-003 Cohort B: Eftilagimod alpha (Soluble LAG-3) and pembrolizumab in first-line recurrent or metastatic head & neck squamous cell carcinoma with PD-L1 negative
Presenter: Martin Forster
Session: Poster Display session
153P - Combination of Tim-3 blockade TQB2618 with PD-1 blockade for patients with immunotherapy-resistant recurrent/metastatic nasopharyngeal carcinoma (R/M NPC): Preliminary results from a phase II study
Presenter: Cheng Xu
Session: Poster Display session
154P - Casdozokitug (casdozo, CHS-388), a first-in-class IL-27 antagonistic antibody, as monotherapy in treatment-refractory non-small cell lung cancer (NSCLC)
Presenter: Aung Naing
Session: Poster Display session